These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22337359)

  • 1. Setting priorities for comparative effectiveness research in inflammatory bowel disease: results of an international provider survey, expert RAND panel, and patient focus groups.
    Cheifetz AS; Melmed GY; Spiegel B; Talley J; Devlin SM; Raffals L; Irving PM; Jones J; Kaplan GG; Kozuch P; Sparrow M; Velayos F; Baidoo L; Bressler B; Siegel CA
    Inflamm Bowel Dis; 2012 Dec; 18(12):2294-300. PubMed ID: 22337359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The appropriateness of concomitant immunomodulators with anti-tumor necrosis factor agents for Crohn's disease: one size does not fit all.
    Melmed GY; Spiegel BM; Bressler B; Cheifetz AS; Devlin SM; Harrell LE; Irving PM; Jones J; Kaplan GG; Kozuch PL; Velayos FS; Baidoo L; Sparrow MP; Siegel CA
    Clin Gastroenterol Hepatol; 2010 Aug; 8(8):655-9. PubMed ID: 20451665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. What is the need for comparative effectiveness studies in IBD?
    Flasar MH; Cross RK
    Expert Rev Gastroenterol Hepatol; 2014 Nov; 8(8):851-4. PubMed ID: 25096481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of Results.
    Melmed GY; Irving PM; Jones J; Kaplan GG; Kozuch PL; Velayos FS; Baidoo L; Sparrow MP; Bressler B; Cheifetz AS; Devlin SM; Raffals LE; Vande Casteele N; Mould DR; Colombel JF; Dubinsky M; Sandborn WJ; Siegel CA
    Clin Gastroenterol Hepatol; 2016 Sep; 14(9):1302-9. PubMed ID: 27189916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
    Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
    Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual therapy with infliximab and immunomodulator reduces one-year rates of hospitalization and surgery among veterans with inflammatory bowel disease.
    Abraham NS; Richardson P; Castillo D; Kane SV
    Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1281-7. PubMed ID: 23792295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel disease.
    Jackson BD; Con D; Liew D; De Cruz P
    Scand J Gastroenterol; 2017 May; 52(5):536-542. PubMed ID: 28128675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What Are the Top 10 Research Questions in the Treatment of Inflammatory Bowel Disease? A Priority Setting Partnership with the James Lind Alliance.
    Hart AL; Lomer M; Verjee A; Kemp K; Faiz O; Daly A; Solomon J; McLaughlin J
    J Crohns Colitis; 2017 Feb; 11(2):204-211. PubMed ID: 27506537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing cancer registry data for comparative effectiveness research (CER) project: overview and methodology.
    Chen VW; Eheman CR; Johnson CJ; Hernandez MN; Rousseau D; Styles TS; West DW; Hsieh M; Hakenewerth AM; Celaya MO; Rycroft RK; Wike JM; Pearson M; Brockhouse J; Mulvihill LG; Zhang KB
    J Registry Manag; 2014; 41(3):103-12. PubMed ID: 25419602
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Comparative Effectiveness Research Priorities for Care Coordination in Chronic Obstructive Pulmonary Disease: A Community-Based eDelphi Study.
    Stellefson M; Alber J; Paige S; Castro D; Singh B
    JMIR Res Protoc; 2015 Aug; 4(3):e103. PubMed ID: 26268741
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory bowel disease: current therapeutic options.
    Domènech E
    Digestion; 2006; 73 Suppl 1():67-76. PubMed ID: 16498254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of topics for comparative effectiveness systematic reviews in the field of cancer imaging.
    Rao M; Concannon TW; Iovin R; Yu WW; Chan JA; Lypas G; Terasawa T; Gaylor JM; Kong L; Rausch AC; Lau J; Kitsios GD
    J Comp Eff Res; 2013 Sep; 2(5):483-95. PubMed ID: 24236745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health priorities in adolescents with inflammatory bowel disease: physicians' versus patients' perspectives.
    Cervesi C; Battistutta S; Martelossi S; Ronfani L; Ventura A
    J Pediatr Gastroenterol Nutr; 2013 Jul; 57(1):39-42. PubMed ID: 23403446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of antitumour necrosis factor-alpha therapy for inflammatory bowel disease in patients post liver transplantation: a case series.
    Sandhu A; Alameel T; Dale CH; Levstik M; Chande N
    Aliment Pharmacol Ther; 2012 Jul; 36(2):159-65. PubMed ID: 22616981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report.
    Feagan BG; Lémann M; Befrits R; Connell W; D'Haens G; Ghosh S; Michetti P; Ochsenkühn T; Panaccione R; Schreiber S; Silverberg M; Sorrentino D; van der Woude CJ; Vermeire S; Rutgeerts P
    Inflamm Bowel Dis; 2012 Jan; 18(1):152-60. PubMed ID: 22038857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefit of Earlier Anti-TNF Treatment on IBD Disease Complications?
    Nuij V; Fuhler GM; Edel AJ; Ouwendijk RJ; Rijk MC; Beukers R; Quispel R; van Tilburg AJ; Tang TJ; Smalbraak H; Bruin KF; Lindenburg F; Peyrin-Biroulet L; van der Woude CJ;
    J Crohns Colitis; 2015 Nov; 9(11):997-1003. PubMed ID: 26223842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knowledge, Attitudes, and Beliefs Regarding the Role of Nutrition in IBD Among Patients and Providers.
    Tinsley A; Ehrlich OG; Hwang C; Issokson K; Zapala S; Weaver A; Siegel CA; Melmed GY
    Inflamm Bowel Dis; 2016 Oct; 22(10):2474-81. PubMed ID: 27598738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality indicators for inflammatory bowel disease: development of process and outcome measures.
    Melmed GY; Siegel CA; Spiegel BM; Allen JI; Cima R; Colombel JF; Dassopoulos T; Denson LA; Dudley-Brown S; Garb A; Hanauer SB; Kappelman MD; Lewis JD; Lynch I; Moynihan A; Rubin DT; Sartor RB; Schwartz RM; Wolf DC; Ullman TA
    Inflamm Bowel Dis; 2013 Mar; 19(3):662-8. PubMed ID: 23388547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.